Composition GHK-Cu: 50 mg BPC-157: 10 mg TB-500 (Thymosin Beta 4): 10 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Combined evaluation of copper peptide, BPC-157, and TB-500 in in-vitro or ex-vivo assay systems Assay development, including chromatographic separation of three co-formulated peptides Stability characterization of a three-analyte lyophilized blend under laboratory storage conditions Method documentation for HPLC/LC-MS identity and purity assessments Documentation Analysis Report Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
Will this program work for me
Diabetes : Nearly 589 million adults worldwide are living with diabetes, projected to reach 853 million by 2050
Dave Asprey: Bulletproof Dave Asprey, founder of Bulletproof Coffee and a pioneer in the Biohacking movement, is a four-time New York Times bestselling author, CEO of Upgrade Labs and Danger Coffee, and host of the Webby award-winning podcast, The Human Upgrade
DPP-4 inhibitors In contrast to GLP-1RAs, dipeptidyl peptidase-4 (DPP-4) inhibitors have minimal, if any, effect on gastric emptying in type 2 diabetes, although their postprandial glucose lowering may be greater in individuals in whom gastric emptying is relatively faster [54]
A widely used antioxidant in cosmetic skincare that helps support skin clarity and protects against environmental stress